SAB Biotherapeutics (SABS) Other Accumulated Expenses (2020 - 2026)

SAB Biotherapeutics (SABS) has 7 years of Other Accumulated Expenses data on file, last reported at $340715.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 54.15% year-over-year to $340715.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $340715.0 (down 54.15% YoY) and the FY2025 annual result came in at $322743.0, down 38.13% from the prior year.
• Other Accumulated Expenses rose to $340715.0 in Q1 2026, from $322743.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.7 million in Q3 2024 to a low of $64850.0 in Q2 2024.
• A 5-year average of $493985.1 and a median of $343102.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses tumbled 76.29% — and 2025, when it surged 1146.51%.
• Tracing SABS's Other Accumulated Expenses over 5 years: stood at $513110.0 in 2022, then fell by 6.37% to $480435.0 in 2023, then advanced by 8.58% to $521639.0 in 2024, then slumped by 38.13% to $322743.0 in 2025, then grew by 5.57% to $340715.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $340715.0 (Q1 2026), $322743.0 (Q4 2025), and $649957.0 (Q3 2025), per Business Quant data.